Genetics and pharmacogenetics of estrogen response

Expert Review of Endocrinology and Metabolism

Volumn 2, Issue 4, 2007, Pages 503-516

  Sala, Silvia Carbonell ^a,b   Martineti, Valentina ^a   Carossino, Anna Maria ^a   Brandi, Maria Luisa ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Spin off DeGene   (Italy)

Author keywords

Estrogen isoforms; Estrogen receptor; Estrogen response; Estrogen related disease; Genetics; Pharmacogenetics; Polymorphism

Indexed keywords

AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GESTAGEN; ISOPROTEIN; PHYTOESTROGEN; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST; BREAST CANCER; CANCER RISK; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLON CANCER; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; ENDOMETRIUM CANCER; ESTROGEN ACTIVITY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOME ANALYSIS; HUMAN; MENOPAUSAL SYNDROME; MONOTHERAPY; NONHUMAN; OBESITY; OSTEOPOROSIS; OVARY; OVARY CANCER; PATHOPHYSIOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN DNA BINDING; PROTEIN FAMILY; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN VARIANT; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS; TISSUE DISTRIBUTION; UTERUS; VAGINA;

EID: 34547561411     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/17446651.2.4.503     Document Type: Review

References (142)

1. Kuiper GG, Carlsson B, Grandien K et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β Endocrinology 138(3), 863-870 (1997).
2. Murdoch FE, Gorski J. The role of ligand in estrogen receptor regulation of gene expression. Mol. Cell Endocrinol. 78(3), C103-C108 (1991).
3. Jensen EV. Steroid hormone antagonists. Summary and future challenges. Ann. NY Acad. Sci. 761, 1-4 (1995).
4. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63, 451-486 (1994).
5. Diel P. Tissue-specific estrogenic response and molecular mechanisms. Taxicol. Lett. 127(1-3). 217-224 (2002).
6. Henderson BE, Ross RK, Paganini-Hill A, Mack TM. Estrogen use and cardiovascular disease. Am. J. Obstet. Gynecol. 154(6), 1181-1186 (1986).
7. Turner CH, Sato M, Bryant HU. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 135(5), 2001-2005 (1994).
8. Fillit H, Weinreb H, Cholst I et al. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology 11 (3), 337-345 (1986).
9. Colditz GA. Epidemtology of breast cancer. Findings from the nurses' health study. Cancer 71 (Suppl. 4), 1480-1489 (1993).
10. Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin. Cancer Res. 9 (6), 1980-1989 (2003).
11. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl Acad. Sd. USA 93(12). 5925-5930 (1996).
12. Li X, Huang J. Yi P, Bambara RA, Hilf R, Muyan M. Single-chain estrogen receptors (ERs) reveal that the ERα/β heterodimer emulates functions of the ERα dimer in genomic estrogen signaling pathways. Mol. Cell Biol. 24(17). 7681-7694 (2004).
13. Kuiper GG, Gustafsson JA. The novel estrogen receptor-β subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett. 410(1), 87-90 (1997).
14. Weyant MJ, Carothers AM, Mahmoud NN et al. Reciprocal expression of ERα and ERβ is associated with estrogen-mediated modulation of intestinal tumorigenesis. Cancer Res. 61(6), 2547-2551 (2001).
15. Ogawa S, Inoue S, Watanabe T et al. Molecular cloning and characterization of human estrogen receptor βcx: a potential inhibitor of estrogen action in human. Nucleic Acids Res. 26(15), 3505-3512 (1998).
16. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270(5240), 1354-1357 (1995).
17. Lavinsky RM, Jepsen K, Heinzel T et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc. Natl Acad. Sci. USA 95(6), 2920-2925 (1998).
18. Mak HY, Hoare S, Henttu PM, Parker MG. Molecular determinants of the estrogen receptor-coactivator interface. Mol. Cell. Biol. 19(5), 3895-3903 (1999).
19. Smith CL, Conneely OM, O'Malley BW. Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. Proc. Natl Acad. Sci. USA 90(13), 6120-6124 (1993).
20. Razandi M, Pedram A, Greene GL, Levin ER. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERα and ERβ expressed in Chinese hamster ovary cells. Mol. Endocrinol. 13(2), 307-319 (1999).
21. Liu YZ, Liu YJ, Recker RR, Deng HW. Molecular studies of identification of genes for osteoporosis: the 2002 update. J. Endocrinol. 177(2), 147-196 (2003).
22. Deroo BJ, Korach KS Estrogen receptors and human disease. J. Clin. Invest. 116(3), 561-570 (2006).
23. Delaunay F. Pettersson K, Tujague M, Gustafsson JA. Functional differences between the amino-terminal domains of estrogen receptors α and β. Mol. Pharmacol. 58(3), 584-590 (2000).
24. Cowley SM, Hoare S, Mosselman S. Parker MG. Estrogen receptors α and β form heterodimers on DNA. J. Biol. Chem. 272(32), 19858-19862 (1997).
25. Pace P, Taylor J, Suntharalingam S, Coombes RC, Ali S. Human estrogen receptor β binds DNA in a manner similar to and dimerizes with estrogen receptor α. J. Biol. Chem. 272(41), 25832-25838 (1997).
26. Pettersson K. Grandien K, Kuiper GG, Gustafsson JA. Mouse estrogen receptor β forms estrogen response element-binding heterodimers with estrogen receptor α. Mol. Endocrinol. 11(10), 1486-1496 (1997).
27. Tremblay A, Tremblay GB. Labrie F. Giguere V. Ligand-independent recruitment of SRC-1 to estrogen receptor β through phosphorylation of activation function AF-1. Mol. Cell 3(4), 513-519 (1999).
28. McInerney EM, Weis KE, Sun J, Mosselman S. Katzenellenbogen BS. Transcription activation by the human estrogen receptor subtype β (ER β) studied with ER β and ER α receptor chimeras. Endocrinology 139(11), 4513-4522 (1998).
29. Paech K, Webb P, Kuiper GG et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 277(5331), 1508-1510 (1997).
30. Benecke A, Chambon P, Gronemeyer H. Synergy between estrogen receptor α activation functions AF1 and AF2 mediated by transcription intermediary factor TIF2. EMBO Rep. 1(2), 151-157 (2000).
31. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc. Natl Acad. Sci. USA 90(23), 11162-11166 (1993).
32. Korach KS, Emmen JM, Walker VR et al. Update on animal models developed for analyses of estrogen receptor biological activity. J. Steroid Biochem. Mol. Biol. 86(3-5), 387-391 (2003).
33. Simpson ER. Models of aromatase insufficiency. Semin. Reprod. Med. 22(1), 25-30 (2004).
34. Weihua Z, Saji S. Makinen S et al. Estrogen receptor (ER) β, a modulator of ERα in the uterus. Proc. Natl Acad Sci. USA 97(11), 5936-5941 (2000).
35. Liu MM, Albanese C, Anderson CM et al. Opposing action of estrogen receptors α and β on cyclin D1 gene expression. J. Biol. Chem. 277(27), 24353-24360 (2002).
36. Lindberg MK, Moverare S, Skrtic S et al. Estrogen receptor (ER)-β reduces ERα-regulated gene transcription, supporting a "ying yang" relationship between ERα and ERβ in mice. Mol. Endocrinol 17(2), 203-208 (2003).
37. Matthews J. Wihlen B, Tujague M, Wan J, Strom A, Gustafsson JA. Estrogen receptor (ER) β modulates ERα-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol. Endocrinol. 20(3), 534-543 (2006).
38. Hirata S, Shoda T, Kato J, Hoshi K. Isoform/variant mRNAs for sex steroid hormone receptors in humans. Trends Endocrinol. Metab. 14(3), 124-129 (2003).
39. Greene GL, Gilna P. Waterfield M, Baker A, Hort Y, Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science 231(4742), 1150-1154 (1986).
40. Ponglikitmongkol M, Green S, Chambon P. Genomic organization of the human oestrogen receptor gene. EMBO J. 7(11), 3385-3388 (1988).
41. Thompson DA, McPherson LA, Carmeci C, deConinck EC, Weigel RJ. Identification of two estrogen receptor transcripts with novel 5′ exons isolated from a MCF7 cDNA library. J. Steroid Biochem. Mol. Biol. 62(2-3), 143-153 (1997).
42. Flouriot G, Griffin C, Kenealy M, Sonntag-Buck V, Gannon F. Differentially expressed messenger RNA isoforms of the human estrogen receptor-α gene are generated by alternative splicing and promoter usage. Mol. Endocrinol. 12(12), 1939-1954 (1998).
43. Kos M, Reid G, Denger S, Gannon F. Minireview: genomic organization of the human ERα gene promoter region. Mol. Endocrinol. 15(12), 2057-2063 (2001).
44. Reid G, Denger S, Kos M, Gannon F. Human estrogen receptor-α: regulation by synthesis, modification and degradation. Cell. Mol. Life Sci. 59(5), 821-831 (2002).
45. Sand P, Luckhaus C, Schlurmann K, Gotz M, Deckert J. Untangling the human estrogen receptor gene structure. J. Neural Transm. 109(5-6), 567-583 (2002).
46. Brand H, Kos M, Denger S et al. A novel promoter is involved in the expression of estrogen receptor α in human testis and epididymis. Endocrinology 143(9), 3397-3404 (2002).
47. Okuda Y, Hirata S, Watanabe N, Shoda T, Kato J, Hoshi K. Novel splicing events of untranslated first exons in human estrogen receptor α (ER α) gene. Endocr. J. 50(1), 97-104 (2003).
48. Hirata S, Shoda T, Kato J, Hoshi K. Novel isoforms of the mRNA for human female sex steroid hormone receptors. J. Steroid Biochem. Mol. Biol. 83(1-5), 25-30 (2002).
49. Flouriot G, Brand H, Denger S et al. Identification of a new isoform of the human estrogen receptor-α (hER-α) that is encoded by distinct transcripts and that is able to repress hER-α activation function 1. EMBO J. 19(17), 4688-4700 (2000).
50. Poola I, Koduri S, Chatra S, Clarke R. Identification of twenty alternatively spliced estrogen receptor α mRNAs in breast cancer cell lines and tumors using splice targeted primer approach. J. Steroid Biochem. Mol. Biol. 72(5), 249-258 (2000).
51. Anandappa SY, Sibson R, Platt-Higgins A, Winstanley JH, Rudland PS, Barraclough R. Variant estrogen receptor α mRNAs in human breast cancer specimens. Int. J. Cancer 88(2), 209-216 (2000).
52. Ye Q, Chung LW, Cinar B, Li S, Zhau HE. Identification and characterization of estrogen receptor variants in prostate cancer cell lines. J. Steroid Biochem. Mol. Biol. 75(1), 21-31 (2000).
53. Koduri S, Poola I. Quantitation of alternatively spliced estrogen receptor α mRNAs as separate gene populations. Steroids 66(1), 17-23 (2001).
54. Bollig A, Miksicek RJ. An estrogen receptor-α splicing variant mediates both positive and negative effects on gene transcription. Mol. Endocrinol. 14(5), 634-649 (2000).
55. Fasco MJ, Keyomarsi K, Arcaro KF, Gierthy JF. Expression of an estrogen receptor α variant protein in cell lines and tumors. Mol. Cell. Endocrinol. 166(2), 156-169 (2000).
56. Horvath G, Leser G, Helou K, Henriksson M. Function of the exon 7 deletion variant estrogen receptor α protein in an estradiol-resistant, tamoxifen-sensitive human endometrial adenocarcinoma grown in nude mice. Gynecol. Oncol. 84(2), 271-279 (2002).
57. Murphy LC, Wang M, Coutt A, Dotzlaw H. Novel mutations in the estrogen receptor messenger RNA in human breast cancers. J. Clin. Endocrinol. Metab. 81(4), 1420-1478 (1996).
58. Pink JJ, Wu SQ, Wolf DM, Bilimoria MM, Jordan VC. A novel 80 kDa human estrogen receptor containing a duplication of exons 6 and 7. Nucleic Acids Res. 24(5), 962-969 (1996).
59. Flouriot G, Brand H, Seraphin B. Gannon F. Natural trans-spliced mRNAs are generated from the human estrogen receptor-α (hER α) gene. J. Biol. Chem. 277(29), 26244-26251 (2002).
60. Tiffoche C, Vaillant C, Schausi D, Thieulant ML. Novel intronic promoter in the rat ER α gene responsible for the transient transcription of a variant receptor. Endocrinology 142(9), 4106-4119 (2001).
61. Lewandowski S, Kalita K, Kaczmarek L. Estrogen receptor β. Potential functional significance of a variety of mRNA isoforms. FEBS Lett. 524(1-3), 1-5 (2002).
62. Hirata S, Shoda T, Kato J, Hoshi K. The multiple untranslated first exons system of the human estrogen receptor β (ER β) gene. J. Steroid Biochem. Mol. Biol. 78(1), 33-40 (2001).
63. Shoda T, Hirata S. Kato J, Hoshi K. Cloning of the novel isoform of the estrogen receptor β cDNA (ERβ isoform M cDNA) from the human testicular cDNA library. J. Steroid Biochem. Mol. Biol. 82(2-3), 201-208 (2002).
64. Poola I, Abraham J, Baldwin K. Identification of ten exon deleted ERβ mRNAs in human ovary, breast, uterus and bone tissues: alternate splicing pattern of estrogen receptor β mRNA is distinct from that of estrogen receptor α. FEBS Lett. 516(1-3), 133-138 (2002).
65. Inoue S, Ogawa S, Horie K et al. An estrogen receptor β isoform that lacks exon 5 has dominant negative activity on both ERα and ERβ. Biochem. Biophys. Res. Commun. 279(3), 814-819 (2000).
66. Price RH Jr, Butler CA, Webb PC, Uht RA, Kushner PJ, Handa RJ. A splice variant of estrogen receptor β missing exon 3 displays altered nuclear localization and capacity for transcriptional activation. Endocrinology 142, 2039-2049 (2001).
67. Moore JT, McKee DD, Slentz-Kesler K et al. Cloning and characterization of human estrogen receptor β isoforms. Biochem. Biophys. Res. Commun. 247(1), 75-78 (1998).
68. Tong D, Schuster E, Seifert M. Czerwenka K, Leodolte S, Zeillinger R. Expression of estrogen receptor β isoforms in human breast cancer tissues and cell lines. Breast Cancer Res. Treat. 71(3), 249-255 (2002).
69. Omoto Y, Kobayashi S, Inoue S et al. Evaluation of oestrogen receptor β wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur. J. Cancer 38(3), 380-386 (2002).
70. Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y, Hayashi S. Estrogen receptor (ER) β1 and ERβcx/β2 inhibit ERα function differently in breast cancer cell line MCF7. Oncogene 22 (32), 5011-5020 (2003).
71. Saunders PT, Millar MR, Macpherson S et al. ERβ1 and the ERβ2 splice variant (ERβcx/β2) are expressed in distinct cell populations in the adult human testis. J. Clin. Endocrinol. Metab. 87(6), 2706-2715 (2002).
72. Esslimani-Sahla M, Kramar A, Simony-Lafontaine J. Warner M, Gustafsson JA, Rochefort H. Increased estrogen receptor βcx expression during mammary carcinogenesis. Clin. Cancer Res. 11(9), 3170-3174 (2005).
73. Wong NA, Malcomson RD, Jodrell DI, Groome NP, Harrison DJ, Saunders PT. ERβ isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. J. Pathol. 207(1), 53-60 (2005).
74. Zhao C, Toresson G, Xu L, Koehler KF, Gustafsson JA, Dahlman-Wright K. Mouse estrogen receptor β isoforms exhibit differences in ligand selectivity and coactivator recruitment. Biochemistry 44(22), 7936-7944 (2005).
75. Morley P, Whitfield JF, Vanderhyden BC, Tsang BK, Schwartz JL. A new, nongenomic estrogen action: the rapid release of intracellular calcium. Endocrinology 131(3), 1305-1312 (1992).
76. Marino M, Pallottini V, Trentalance A. Estrogens cause rapid activation of IP3-PKC-α signal transduction pathway in HEPG2 cells. Biochem. Biophys. Res. Commun. 245(1), 254-258 (1998).
77. Warner M, Gustafsson JA. Nongenomic effects of estrogen: why all the uncertainty? Steroids 71(2), 91-95 (2006).
78. Losel RM, Falkenstein E, Feuring M et al. Nongenomic steroid action: controversies, questions, and answers. Physiol. Rev. 83(3), 965-1016 (2003).
79. Taguchi Y, Koslowski M, Bodenner DL. Binding of estrogen receptor with estrogen conjugated to bovine serum albumin (BSA). Nucl. Recept. 2(1), 5 (2004).
80. Bjornstrom L. Sjoberg M. Signal transducers and activators of transcription as downstream targets of nongenomic estrogen receptor actions. Mol. Endocrinol. 16(10), 2202-2214 (2002).
81. Marino M, Acconcia F, Trentalance A. Biphasic estradiol-induced AKT phosphorylation is modulated by PTEN via MAP kinase in HepG2 cells. Mol. Biol. Cell 14(6), 2583-2591 (2003).
82. Mazumdar A, Kumar R. Estrogen regulation of Pak1 and FKHR pathways in breast cancer cells. FEBS Lett. 535(1-3), 6-10 (2003).
83. Sukocheva CA, Wang L, Albanese N. Pitson SM, Vadas MA, Xia R Sphingosine kinase transmits estrogen signaling in human breast cancer cells. Mol. Endocrinol. 17(10). 2002-2012 (2003).
84. Mishra S, Reichert A, Cunnick J et al. Protein kinase CKIIα interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cell. Oncogene 22(51), 8255-8262 (2003). Erratum in: Oncogene 23(37), 6325 (2004).
85. Acconcia F, Totta P, Ogawa S et al. Survival versus apoptotic 17β-estradiol effect: role of ER α and ER β activated non-genomic signaling. J. Cell Physiol. 203(1), 193-201 (2005).
86. Chambliss KL, Shaul PW. Estrogen modulation of endothelial nitric oxide synthase. Endocr. Rev. 23(5), 665-686 (2002).
87. Toran-Allerand CD, Guan X MacLusky NJ et al. ER-X: a novel, plasma membrane-associated, putative estrogen receptor that is regulated during development and after ischemic brain injury. J. Neurosci. 22(19), 8391-8401 (2002).
88. 2+ rise and subsequent cyclic AMP response element-binding protein activation in hippocampal neurons: a potential Initiation mechanism for estrogen neurotrophism. Neuroscience 132(2), 299-311 (2005).
89. Abraham IM, Todman MG, Korach KS, Herbison A.E. Critical in vivo roles for classical estrogen receptors in rapid estrogen actions on intracellular signaling in mouse brain. Endocrinology 145 (7), 3055-3061 (2004).
90. Zhang X, Bruice TC. The proficiency of a thermophilic chorismate mutase enzyme is solely through an entropic advantage in the enzyme reaction. Proc. Natl. Acad Sci. USA 102(51), 18356-18360 (2005).
91. Filardo EJ, Quinn JA, Frackelton AR Jr. Bland KI. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-medlated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol. Endocrinol. 16(1), 70-84 (2002).
92. Gennari L, Becherini L, Falchetti A, Masi L, Massart F, Brandi ML. Genetics of osteoporosis: role of steroid hormone receptor gene polymorphisms. J. Steroid Biochem. Mol. Biol. 81(1), 1-24 (2002).
93. Zuppan PJ. Hall JM, Ponglikitmongkol M, Spielman R, King MC. Polymorphisms at the estrogen receptor (ESR) locus and linkage relationships on chromosome 6q. Cytogenet. Cell Genet. 51, 1116 (1989).
94. Yaich L, Dupont WD, Cavener DR, Parl FF. Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. Cancer Res. 52, 77-83 (1992).
95. Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN. Proportion of breast cancer cases in the United States explained by well-established risk factors. J. Natl. Cancer Inst. 87 (22), 1681-1685 (1995).
96. Cal Q, Shu XO, Jin F et al. Genetic polymorphisms in the estrogen receptor a gene and risk of breast cancer: results from the Shanghai Breast Cancer Study. Cancer Epidemiol. Biomarkers Prev. 12, 853-859 (2003).
97. Onland-Moret NC, van Gils CH. Roest M, Grobbee DE, Peeters PH. The estrogen receptor a gene and breast cancer risk (The Netherlands). Cancer Causes Control 16(10), 1195-1202 (2005).
98. Zheng SL, Zheng W, Chang BL et al. joint effect of estrogen receptor β sequence variants and endogenous estrogen exposure on breast cancer risk in Chinese women. Cancer Res. 63, 7624-7629 (2003).
99. Maguire P, Margolin S, Skoglund J et al. Estrogen receptor B (ESR2) polymorphisms in familial and sporadic breast cancer. Breast Cancer Res. Treat. 94, 145-152 (2005).
100. Arai N. Strom A, Rafter JJ, Gustafsson JA. Estrogen receptor β mRNA in colon cancer cells: growth effects of estrogen and genistein. Biochem. Biophys. Res. Commun. 270, 425-431 (2000).
101. Fiorelli G. Picariello L, Martineti V, Tonelli F, Brandi ML. Functional estrogen receptor β in colon cancer cells. Biochem. Biophys. Res. Commun. 261, 521-527 (1999).
102. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW. Selective loss of estrogen receptor β in malignant human colon. Cancer Res. 60, 245-248 (2000).
103. Martineti V, Picariello, L, Tognarini I et al. ERβ is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components. Endocr. Relat. Cancer 12(2), 455-469 (2005) Erratum in: Endocr. Relat. Cancer 12(3), 682 (2005).
104. Harris HA, Albert LM, Leathurby Y et al. Evaluation of an estrogen receptor-β agonist in animal models of human disease. Endocrinology 144, 4241-4249 (2003). Erratum in: Endocrinology. 147(5). 2085 (2006).
105. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J. Clin. 54, 8-29 (2004).
106. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002).
107. Slattery ML, Sweeney C, Murtaugh M et al. Associations between ERα, ERβ, and AR genotypes and colon and rectal cancer. Cancer Epidemiol. Biomarkers Prev. 14(12), 2936-2942 (2005).
108. Huber A, Bentz EK, Schneeberger G, Huber JC, Hefler L, Tempfer C. Ten polymorphisms of estrogen-metabolizing genes and a family history of colon cancer - an association study of multiple gene-gene interactions. J. Soc. Gynecol. Investig. 12(7). E51-E54 (2005).
109. Wu HJ, Sekine M, Kashima K et al. Mutational analysis of the estrogen receptor-α gene in familial ovarian cancer. J. Obstet. Gynaecol. Res. 31(5), 375-83 (2005).
110. Thellenberg-Karlsson C, Lindstrom S. Malmer B et al. Estrogen receptor β polymorphism is associated with prostate cancer risk. Clin. Cancer Res. 12(6), 1936-1941 (2006).
111. Hernandez J, Balic I, Johnson-Pals TL et al. Association between an estrogen receptor α gene polymorphism and the risk of prostate cancer in black men. J. Urol. 175(2), 523-527 (2006).
112. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchom Arch. 444, 213-223 (2004).
113. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet. Gynecol. 85, 304-313 (1995).
114. Georgopoulos NA, Adonakis GL, Fotopoulos A et al. Estrogen receptor polymorphisms in tamoxifen-treated women with breast cancer. Gynecol Endocrinol. 22(4), 185-189 (2006).
115. Carbonell Sala S, Masi L, Marini F et al. Genetics and pharmacogenetics of osteoporosis. J. Endocrinol. Invest. 28(10 Suppl.), 2-7 (2005).
116. Ioannidis JPA, Ralston SH, Bennett ST et al. Differential genetic effects of ESR1 gene polymorphisms on osteoporotic outcomes. JAMA 292(17), 2105-2114 (2004).
117. Rivadeneira F, van Meurs JB, Kant J et al. Estrogen receptor β (ESR2) polymorphisms in interaction with estrogen receptor a (ESR1) and insulin-like growth factor I (IGF1) variants influence the risk of fracture in postmenopausal women. J. Bone Miner. Res. 21(9), 1443-56 (2006).
118. Shearman AM, Karasik D, Gruenthal KM et al. Estrogen receptor β polymorphisms are associated with bone mass in women and men: the Framingham Study. J. Bone Miner. Res. 19(5), 773-781 (2004).
119. Wang X Dykens A Perez E et al. Neuroprotective effects of 17β-estradiol and nonfeminizing estrogens against H2O2 toxicity in human neuroblastoma SK-N-SH cells. Mol. Pharmacol. 70(1), 395-404 (2006).
120. Shearman AM, Cooper JA, Kotwinski PJ et al. Estrogen receptor a gene variation and the risk of stroke. Stroke 36 (10), 2281-2282 (2005).
121. Westberg L, Hakansson A, Melke J et al. Association between the estrogen receptor β gene and age of onset of Parkinson's disease. Psychoneuroendocrinology 29(8), 993-998 (2004).
122. Hakansson A. Westberg L, Nilsson S et al. Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor β on the susceptibility to Parkinson's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 133(1), 88-92 (2005).
123. Usui C, Shibata N, Ohnuma T et al. No genetic association between the myeloperoxidase gene -463 polymorphism and estrogen receptor-α gene polymorphisms and Japanese sporadic Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 21(5-6), 296-299 (2006).
124. Corbo RM, Gambina G, Ruggeri M, Scacchi R. Association of estrogen receptor α (ESR1) PvuII and XbaI polymorphisms with sporadic Alzheimer's disease and their effect on apolipoprotein E concentrations. Dement. Geriatr. Cogn. Disord. 22(1), 67-72 (2006).
125. Monastero R, Cefalu AB, Camarda C et al. Association of estrogen receptor α gene with Alzheimer's disease: a case-control study. J. Alzheimers Dis. 9(3). 273-278 (2006).
126. Rokach A, Pollak A, Rosen L et al. Estrogen receptor a gene polymorphisms are associated with the angiographic extent of coronary artery disease. J. Clin. Endocrinol. Metab. 90(12), 6556-6560 (2005).
127. Shearman AM, Cupples LA, Demissie S et al. Association between estrogen receptor α gene variation and cardiovascular disease. JAMA 290, 2263-2270 (2003).
128. Peter I, Shearman AM, Zucker DR et al. Variation in estrogen-related genes and cross-sectional and longitudinal blood pressure in the Framingham Heart Study. J. Hypertens. 23, 2193-2200 (2005).
129. Ellis JA, Infantino T, Harrap SB. Sex-dependent association of blood pressure with estrogen receptor genes ERα and ERβ. J. Hypertens. 22, 1127-1131 (2004).
130. Schuit SC, Oei HH, Witteman JC et al. Estrogen receptor a gene polymorphisms and risk of myocardial infarction. JAMA 291, 2969-2977 (2004).
131. Peter I. Shearman AM, Vasan RS et al. Association of estrogen receptor β gene polymorphisms with left ventricular mass and wall thickness in women. Am. J. Hypertens. 18, 1388-1395 (2005).
132. Zhu Y, Bian Z, Lu P et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor β. Science 295, 505-508 (2002).
133. Okura T, Koda M, Ando F, Niino N, Ohta S, Shimokata H. Association of polymorphisms in the estrogen receptor α gene with body fat distribution. Int. J Obes. Relat. Metab. Disard. 27(9), 1020-1027 (2003).
134. Massart F. Human races and pharmacogenomics of effective bone treatments. Gynecol. Endocrinol. 20(1), 36-44 (2005).
135. Tempfer CB, Schneeberger C, Huber JC. Applications of polymorphisms and pharmacogenomics in obstetrics and gynecology. Pharmacogenomics 5 (1), 57-65 (2004).
136. Herrington DM, Howard TD, Hawkins GA et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N. Engl. J. Med. 346(13), 967-974 (2002).
137. Herrington DM, Howard TD. ER-α variants and the cardiovascular effects of hormone replacement therapy. Pharmacogenomics 4(3), 269-277 (2003).
138. Slattery ML, Sweeney C, Herrick J et al. ESR1, AR, body size, and breast cancer risk in Hispanic and non-Hispanic white women living in the Southwestern United States. Breast Cancer Res. Treat. (2006) (Epub ahead of print).
139. Masi L, Ottanelli S, Del Monte F et al. Aromatase and estrogen receptor α gene polymorphisms: response of the bone mineral density in post-menopausal women to HRT. Presented at: XXVI Annual Meeting of the ASBMR. Seattle, USA, October 1-5 SU181 (2004).
140. Silvestri S, Thomsen AB, Gozzini A. Bagger Y, Christiansen C, Brandi ML. Estrogen receptor α and β polymorphisms: is there an association with bone mineral density, plasma lipids, and response to postmenopausal hormone therapy, Menopause 13(3), 451-461 (2006).
141. Yim CH. Choi JT, Choi HA et al. Association of estrogen receptor α gene microsatellite polymorphism with annual changes in bone mineral density in Korean women with hormone replacement therapy. J. Bone Miner. Metab. 23(5), 395-400 (2005).
142. Yoneda K, Tanji Y, Ikeda N et al. Influence of adjuvant tamoxifen treatment on bone mineral density and bone turnover markers in postmenopausal breast cancer patients in Japan. Cancer Lett. 186(2), 223-230 (2002).